<DOC>
	<DOC>NCT01903122</DOC>
	<brief_summary>The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions</brief_summary>
	<brief_title>Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions</brief_title>
	<detailed_description />
	<mesh_term>Cevimeline</mesh_term>
	<criteria>No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to cevimeline or any comparable or similar product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>